publication date: May. 20, 2016
NCI is working to provide five to ten recommendations for Vice President Joe Biden’s cancer moonshot program, officials said at a recent advisory committee meeting.
At a meeting of the Frederick National Laboratory Advisory Committee May 11, top NCI officials described the mechanisms that will be used to provide recommendations for spending new money that may be directed at cancer research.
The institute’s Blue Ribbon Panel—consisting of 28 members representing academia, government, industry and patient advocates—has assembled seven working groups.
Vice President Joe Biden’s National Cancer Moonshot Initiative has touched off an unprecedented national and international dialogue about cancer.
My presidential year at the American Association for Cancer Research brings the special opportunity to ensure that this momentum is captured and fully utilized to position cancer research as the key to saving more lives from cancer.
The AACR has been and continues to be a trusted adviser to the vice president on this important initiative.
House Committee Provides Forum for Opponents of Part B Payment Model
A Congressional committee earlier this week provided a venue for opponents of a controversial Medicare Part B payment model to argue against its implementation by Centers for Medicaid Services.
Witnesses at the May 17 hearing of the health subcommittee of the House Committee on Energy and Commerce said the payment model would make it difficult for Medicare patients to obtain care, and one witness likened the model to an unethical clinical trial. Also, in what couldn’t be a coincidence, two witnesses—representing patients with immune deficiencies and rheumatology—submitted written testimony that contained identical paragraphs.
- James Brink elected chair of American College of Radiology
Michael Kaplan named president and CEO of Melanoma Research Alliance
Hong-yu Li named Arkansas Research Alliance Scholar and endowed chair
CPRIT awards 35 grants totaling $79.2 million
Senate marks up FDA tobacco regulation appropriations
|Drugs and Targets|